US 8632825B2
· Velasco Diez et al.
· 2014
[cited by applicant]
US 8790719B2
· Parolaro et al.
· 2014
[cited by applicant]
US 9017737B2
· Kikuchi et al.
· 2015
[cited by applicant]
US 9125859B2
· Whalley et al.
· 2015
[cited by applicant]
US 9474726B2
· Guy et al.
· 2016
[cited by applicant]
US 9675654B2
· Parolaro et al.
· 2017
[cited by applicant]
US 9949936B2
· Guy et al.
· 2018
[cited by applicant]
US 9949937B2
· Guy et al.
· 2018
[cited by applicant]
US 9956183B2
· Guy et al.
· 2018
[cited by applicant]
US 9956184B2
· Guy et al.
· 2018
[cited by applicant]
US 9956185B2
· Guy et al.
· 2018
[cited by applicant]
US 9956186B2
· Guy et al.
· 2018
[cited by applicant]
US 9962341B2
· Stott et al.
· 2018
[cited by applicant]
US 10220005B2
· Martinez-Orgado et al.
· 2019
[cited by applicant]
US 20170239193A1
· Guy et al.
· 2017
[cited by applicant]
US 20180071210A1
· Wilkhu et al.
· 2018
[cited by applicant]
US 20200138738A1
· Guy et al.
· 2020
[cited by applicant]
US 20200179303A1
· Guy et al.
· 2020
[cited by applicant]
US 20200206153A1
· Whalley et al.
· 2020
[cited by applicant]
US 20200352878A1
· Guy et al.
· 2020
[cited by applicant]
US 20210052512A1
· Guy et al.
· 2021
[cited by applicant]
US 20210059949A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210059976A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210069333A1
· Velasco Diez et al.
· 2021
[cited by applicant]
US 20210169824A1
· Guy et al.
· 2021
[cited by applicant]
US 20210330636A1
· Guy et al.
· 2021
[cited by applicant]
US 20220008355A1
· Guy et al.
· 2022
[cited by applicant]
US 20220016048A1
· Guy et al.
· 2022
[cited by applicant]
US 20220023232A1
· Guy et al.
· 2022
[cited by applicant]
US 20220087951A1
· Knappertz
· 2022
[cited by applicant]
US 20220183997A1
· Guy et al.
· 2022
[cited by applicant]
US 20220184000A1
· Guy et al.
· 2022
[cited by applicant]
US 20220202738A1
· Guy et al.
· 2022
[cited by applicant]
US 20220211629A1
· Wilkhu et al.
· 2022
[cited by applicant]
US 20220226257A1
· Guy et al.
· 2022
[cited by applicant]
US 20220233495A1
· Silcock et al.
· 2022
[cited by applicant]
US 20220249396A1
· Guy et al.
· 2022
[cited by applicant]
US 20220257529A1
· Guy et al.
· 2022
[cited by applicant]
US 20220378714A1
· Guy et al.
· 2022
[cited by applicant]
US 20220378715A1
· Guy et al.
· 2022
[cited by applicant]
US 20220378738A1
· Guy et al.
· 2022
[cited by applicant]
US 20230032502A1
· Guy et al.
· 2023
[cited by applicant]
US 20230038423A1
· Silcock et al.
· 2023
[cited by applicant]
US 20230143812A1
· Knappertz et al.
· 2023
[cited by applicant]
US 20230277560A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277561A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277562A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277563A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285419A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285420A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285421A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285422A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285423A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285424A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285426A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285428A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230310464A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230372367A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230372368A1
· Checketts et al.
· 2023
[cited by applicant]
US 20240016819A1
· Craig
· 2024
[cited by applicant]
US 20240025858A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240033229A1
· Guy et al.
· 2024
[cited by applicant]
US 20240033272A1
· Checketts et al.
· 2024
[cited by applicant]
US 20240050452A1
· Craig et al.
· 2024
[cited by applicant]
GB 2531278A
· 2016
[cited by applicant]
GB 2531282A
· 2016
[cited by applicant]
WO WO2016176279A1
· 2016
[cited by examiner]
WO WO2019207319A1
· 2019
[cited by applicant]
WO WO2020109806A1
· 2020
[cited by applicant]
Baldassari, S. et al., “The landscape of epilepsy-related GATOR1 variants,” Genet Med., 21(2):398-408 (2019); doi:10.1038/s41436-018-0060-2. Epub Aug. 10, 2018.
[cited by applicant]
Bonaglia, M. C. et al., “Partial deletion of DEPDC5 in a child with focal epilepsy,” Epilepsia Open, 1(3-4):140-144 (2016). Published online Aug. 25, 2016. doi: 10.1002/epi4.12012.
[cited by applicant]
Caraballo, R. et al., “Effectiveness of cannabidiol in a prospective cohort of children with drug resistant epileptic encephalopathy in Argentina,” Seizure: European Journal of Epilepsy, 80:75-80 (2020).
[cited by applicant]
Eadie, M. J., “Shortcomings in the current treatment of epilepsy,” Expert Rev Neurother., 12(12):1419-1427 (2012).
[cited by applicant]
Elsohly, M. & Gul, W., Handbook of Cannabis, Chapter 1, Constituents of Cannabis Sativa, Roger Pertwee, Ed., 2012, 21 pages.
[cited by applicant]
EPIDIOLEX® (cannabidiol) oral solution, CV, Prescribing Information, 2018, 30 pages; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.
[cited by applicant]
Hausman-Kedem, M. et al., “Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents—An observational, longitudinal study,” Brain Dev., 40(7):544-551 (2018); doi: 10.1016…
[cited by applicant]
Kwan, P. et al., “Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies,” Epilepsia, 51(6):1069-1077; doi:10.1111/j.1528-1167.2009.02397.x. E…
[cited by applicant]
Laux, L. C. et al., “Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results,” Epilepsy Research, 154:13-2…
[cited by applicant]
Pertwee, R. G., “The Pharmacology and Therapeutic Potential of Cannabidiol,” Cannabinoids, Chapter 3, DiMarzo, V. (Ed.), pp. 32-83 (2004).
[cited by applicant]
Picard, F. et al., “DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy,” Neurology, 82:2101-2106 (2014).
[cited by applicant]
Porter, B. E. & Jacobson, C., “Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy,” Epilepsy Behav., 29(3):574-577 (2013).
[cited by applicant]
Rosenberg, E. C. et al., “Quality of Life of Childhood Epilepsy (QOLCE) in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol (CBD),” Epilepsia, 58(8):e96-e100 (2017); doi:10.1111/e…
[cited by applicant]
Silvestro, S. et al., “Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials,” Molecules, 24:1459 (2019), 25 pages; doi:10.3390/molecules24081459.
[cited by applicant]
Stockings, E. et al., “Evidence for cannabis and cannabinoids for epilepsy: a systematic review of a controlled and observational evidence,” J. Neurol Neurosurg Psychiatry, 89:741-753 (2018); doi: 10.1136/jnnp-2017-3171…
[cited by applicant]
Szaflarski, J. P. et al., “Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results,” Epilepsia, 59:1540-1548 (2018).
[cited by applicant]
Thurman, D. J. et al., “Standards for epidemiologic studies and surveillance of epilepsy,” Epilepsia, 52 (Suppl 7):2-26 (2011).
[cited by applicant]
Chiron, C. & Dulac, O., “The pharmacologic treatment of Dravet syndrome,” Epilepsia, 52(Suppl 2):72-5 (Apr. 2011).
[cited by applicant]
Kelley, S. A. & Kossoff, E. H., “Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress,” Developmental Med. & Child Neurol., 52(11):988-93 (Nov. 2010).
[cited by applicant]
Lutz, B. et al., “On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures,” Biochemical Pharmacology 68:1691-1698 (Nov. 2004).
[cited by applicant]
Mayo Clinic, “Carbamazepine (oral route),” [drug information], provided by Merative, Micromedex®, DRG-20062739, (initial publication date unknown; last updated Feb. 1, 2026). [Retrieved from the Internet on Feb. 12, 202…
[cited by applicant]
Mayo Clinic, “Phenytoin (oral route),” [drug information], provided by Merative, Micromedex®, DRG-20072875, (initial publication date unknown; last updated Feb. 1, 2026). [Retrieved from the Internet on Feb. 12, 2026; a…
[cited by applicant]
Scheffer, I. E. et al., “Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder,” Brain, 118(Pt 1):61-73 (Feb. 1995). doi: 10.1093/brain/118.1.61.
[cited by applicant]
U.S. Food and Drug Administration, “What We Do,” [website] FDA.gov., U.S. Department of Health and Human Services, (initial publication date unknown; last updated Nov. 21, 2023). [Retrieved from the Internet on Feb. 12,…
[cited by applicant]
Vossler, D. G. & Gidal, B. E., “A summary of antiseizure medications available in the United States: 4th Edition,” American Epilepsy Society, (Revised Apr. 1, 2024), 28 pages.
[cited by applicant]